

Neurochirurgie guidée par l'image



Emmanuel Mandonnet

Service de Neurochirurgie du Pr Froelich

Hôpital Lariboisière

Laboratoire IMNC Paris 7 - UMR 8165



mandonnet@mac.com

27/05/2014



Gliomes diffus de bas grade

◆ Grade II de l'OMS

- astrocytome, oligodendrogliome
- 10 % des gliomes
- incidence : 0.55-0.8/100 000/an
- patients jeunes (30-40 ans)
- médiane de survie : 10 ans (**grande hétérogénéité**)




Extension invisible



Pallud & al. 2010, *Neurology*


The number of cycling cells is expressed as MIB-1-positive cells per square centimeter, and the distance from MRI-defined abnormalities is expressed in millimeters. OutBS = biopsy sample taken outside MRI-defined abnormalities.

Natural history of a diffuse low-grade glioma



Plasticité cérébrale et cinétique tumorale


- ◆ Asymptomatique (90 % des cas) car la lenteur de l'évolution permet la mise en place des phénomènes de plasticité
- ◆ Asymptomatique mais ...
 - déficits aux examens neuropsychologiques
 - déficits aux examens d'orthophonie
 - retentissement socio-professionnel




Problématiques du chirurgien

- ◆ Faut-il opérer ?
- ◆ Comment opérer ?



The pro & cons balance (in the 20th century)





LGG are evolutive tumors, albeit looking stable !




LGG are evolutive tumors, albeit looking stable !



LGG are evolutive tumors



Quantitative morphological MRI follow-up




Sorensen & al. 2001, *JCO*

Pallud & al. 2012, *Neurosurgery*

Schmitt & al. 2013, *J Neurooncol*

The beginning of the story




**Buster
Alvord**



**James
Murray**

Is tumor volume growing exponentially ?



In silico glioma growth


Model equation

variable : cell density


tunable parameters : D ,

$$\frac{\partial c}{\partial t} = \nabla \cdot (D \nabla c) + \rho c$$


In silico glioma growth : virtual cell density maps



Tracqui & al.
Cell Prolif
1995



Swanson & al.
Cell Prolif
2000



Jbabdi & al.
MRM
2005


In silico glioma growth

Model equation

variable : cell density


tunable parameters : D ,

**anatomical
knowledge**





Virtual cell density maps

$$\frac{\partial c}{\partial t} = \nabla \cdot (D \nabla c) + \rho c$$



Cell density threshold of visibility




Konukoglu & al. 2011, *MedIA*


The number of cycling cells is expressed as MIB-1-positive cells per square centimeter, and the distance from MRI-defined abnormalities is expressed in millimeters. OutBS = biopsy sample taken outside MRI-defined abnormalities.

Pallud & al. 2010, *Neurology*

Cell density threshold of visibility



Gerin & al. 2013, *Neurooncol*



In silico glioma growth


Model equation

variable : cell density


tunable parameters : D ,

$$\frac{\partial c}{\partial t} = \nabla \cdot (D \nabla c) + \rho c$$


**anatomical
knowledge**



Virtual cell density maps




**visibility
threshold**



Virtual longitudinal MRIs



A simplified version of the model ...



$$\text{velocity} = 2\sqrt{(\mathbf{D})}$$




$$\text{Etendue} \approx \exp(\sqrt{(\mathbf{D} / \rho)})$$

Converting volumes to diameters



$$D = (2V)^{1/3}$$


VDE of Grade II Gliomas before treatment



VDE = 4 mm/year


Intérêt pronostique

Survival Analysis




Pallud, Mandonnet & al. 2006, *Ann Neurol*

The pro & cons balance



Survival benefit of surgical resection




**Jakola
& al.,
2012
*JAMA***


No. of patients at risk

Biopsy preferred	66	46	36	21	11	6
Resection preferred	87	71	50	40	23	13

The pro & cons balance



Awake surgery with brain mapping




The pro & cons balance

Less **initial** risk of
functioning deterioration

Minimal risk of
functioning
deterioration
Improved survival
Evolutionary tumor



WAIT & WATCH

SURGERY




Suivi sous Temozolomide

After TMZ onset



After TMZ disruption



Ricard & al. 2007, *Annals of Neurology*

La radiothérapie


Pas d'effet dose (64 vs 50 vs 45 Gy)

Irradiation précoce


- impact PFS
- pas de bénéfice sur la survie globale

Cliniquement

- effet bénéfique sur les crises
- déficits cognitifs à long terme




Number of patients at risk	N	0	1	2	3	4	5	6	7	8
No early radiotherapy	157	118	94	78	57	40	31	17	11	
Early radiotherapy	154	140	119	107	89	66	47	35	18	



Number of patients at risk	N	0	1	2	3	4	5	6	7	8
No early radiotherapy	157	144	133	123	111	97	83	69	58	5
Early radiotherapy	154	144	138	122	107	81	66	52	41	4

(van den Bent & al. 2005, *Lancet*)


But d'un traitement oncologique



Time to malignant transformation

Time to death


Principes du traitement





Problématiques du chirurgien

- ◆ **Quand** faut-il opérer **ce patient** ?
- ◆ Comment opérer ?

Natural history of a diffuse low-grade glioma



DLGG of incidental discovery



Two series

- 47 patients
- 35 patients

Small tumors

(3cm versus 5cm)

But same growth rates !!!

Pallud & al. 2010, *Annals of Neurology*

Potts & al. 2012, *JNS*

Pallud & Mandonnet 2013, *JNS*

When diagnosed, the glioma is already old ...

$\Delta t = \text{duration of silent period} = D_{\text{initial}} / V_{\text{initiale}}$

Retrospective series of 148 patients

$\Delta t = 15 \text{ years} !!!$

Pallud & al. , 2013. *Acta Neurochir*

Silent period : is it when we missed the action ?

During these 15 years of silent evolution :

- microscopic cellular invasion (undetectable on MRI)
→ no surgical cure
- acquisition and accumulation of genomic mutations
→ chemoresistance

Should we set a screening policy ?




Figure 6: Mobile MRI unit at the reflecting pool in Washington, DC offering scans to members of the U.S Congress and their staffs. Results? Classified.


Kelly P. 2010, *Surgical Neurology International*

What about overdiagnosis (and overtreatment) ?

Natural history of silent diffuse low-grade glioma



Dying *from* versus *with* a silent diffuse low-grade glioma





Mandonnet & al. 2014
Cancer

Cost-effectiveness analysis

- ◆ **Cost for one MRI (single flair sequence) : \$ 150**
- ◆ **For 10 000 people : \$ 1 500 000**
- ◆ **Among these : 4 people with a silent DLGG**
- ◆ **Cost of a person-year : \$ 120 000**
- ◆ **Balance reached if early treatment saves 3 years of **active life****

Using the time-machine



Automated tools of MRI analysis

- ◆ **Class of age : about 750 000 people in France**
 - 750 000 MRIs = 250 full time neuroradiologists
- ◆ **Need of computational algorithms**
 - evaluate their sensitivity and specificity
 - assume a sensitivity of 100 % :
 - A specificity as low as 10 % : $4 \times 75 \times 10$ to be interpreted by an expert (= 1 neuroradiologist full time)

Quand opérer ce patient ?

Quand on espère pouvoir améliorer sa survie
(tout en conservant ou améliorant sa qualité de vie)

Modifier l'histoire naturelle

- quelle est la dynamique du patient ?
 - vitesse d'évolution

Case: 404

Case < > Case

Select Case

4

Load

Show CD Overlay

Show Findings

Cross Hair

Base Exam on top

Link

Subtract Images

Subtract Comparison Image

Base Follow

Create Finding

Adjust Finding


Delete Finding

Image < > Image

Pause...

Write + Exit

Reset W/L



Erickson & al., 2011. AJNR

How to match contrast between two images ?

$$H_{midway} = \left(\sqrt{H_{I_1}^{-1} H_{I_2}^{-1}} \right)^{-1}$$


$$I_{midway1} = H_{midway}^{-1} \circ H_{I_1}(I_1) = \sqrt{I_1 \times H_{I_2}^{-1} \circ H_{I_1}(I_1)}$$

$$I_{midway2} = H_{midway}^{-1} \circ H_{I_2}(I_2) = \sqrt{I_2 \times H_{I_1}^{-1} \circ H_{I_2}(I_2)}$$

Angelini & al., 2012, *MedIA*

Delon J. 2004. *Journal of Mathematical Imaging and Vision*

Computational methods of change detection



Angelini & al. 2011, *MedIA*

Quand opérer ce patient ?

Quand on espère pouvoir améliorer la survie
tout en conservant ou améliorant sa qualité de vie



Modifier l'histoire naturelle

- quelle est la dynamique ?
 - vitesse d'évolution
 - invasivité

Effect of surgery

Swanson & al. 2003, *J Neurol Sc*

Grade	ρ (1/day)	D (cm ² /day)	Gross Total % Resected	Survival Time (days)	Extensive % Resected	Survival Time (days)
HH	0.012	0.0013	36.9	127	86.7	254
HL	0.012	0.00013	95.5	421	99.9	869
LH	0.0012	0.0013	12.5	130	55.7	1079
LL	0.0012	0.00013	36.9	1273	86.7	2537



Yordanova & al. 2011, *JNS*

The « inverse » problem

D, : tunable parameters


How to determine their values for a specific patient ?

1. Cell biology measurements

- : MIB-1, cell cycle time ?
- D : *in vitro* cell migration experiments

2. Image-based determination

Making the model patient-specific



Towards patient-specific modeling



(a) First Image




(b) 2nd image taken 39 days after the first one



(e) Final image taken 390 days after the first one



(f) Another slice of the final image



(c) 3rd image taken 121 days after the first one




(d) 4th image taken 210 days after the first one


$\rho(\text{set})$	d_w	d_g
0.008 1/day	0.15 mm ² /day	5x10 ⁻⁴ mm ² /day

Konukoglu & al. 2010, *IEEE*


In silico glioma growth : virtual cell density maps



Tracqui & al.
Cell Prolif
1995



Swanson & al.
Cell Prolif
2000



Jbabdi & al.
MRM
2005

?

cell
density
estimation

?

2015


Quand opérer ce patient ?

Quand on espère améliorer la survie
(tout en conservant ou améliorant sa qualité de vie)

Modifier l'histoire naturelle

- quelle est la dynamique ?
 - vitesse d'évolution
 - invasivité
- quelle sera l'étendue de l'exérèse en allant jusqu'aux limites fonctionnelles ?

Survival benefit of surgical resection



**Smith
& al.,
2008
*JCO***


Quand opérer ce patient ?

Quand on espère améliorer la survie
tout en conservant ou améliorant sa qualité de vie


Modifier l'histoire naturelle

- quelle est la dynamique ?
 - vitesse d'évolution
 - invasivité
- quelle sera l'étendue de l'exérèse en allant jusqu'aux limites fonctionnelles?
 - **supratotale / totale / subtotale** / partielle


Probabilistic atlas of functional resectability



Pre-operative estimation of residual volume



Validating the reproducibility of a surgical technique



Problématiques du chirurgien

- ◆ Quand faut-il opérer ce patient ?
- ◆ **Comment opérer ?**

Planning pré-chirurgical : IRMf

Principe


- effet BOLD

Avantages

- non invasif

Inconvénients

- aires activées mais non essentielles
- Sensibilité et spécificité limitées par la tumeur, qui perturbe l'hémodynamique



Planning pré-chirurgical : DTI

Principe



- tenseur de diffusion de l'eau
- puis algorithme de tracking à partir d'un ou plusieurs ROI

Avantages

- non invasif

Inconvénients

- tracking
- fonction ?



En per-opératoire : navigation anatomique




Figure 15 : Principe de triangulation des systèmes de repéra

Neuronavigation anatomique (2)


Avantages

- aide précieuse à la localisation 3D
- possibilité d'intégrer le planning préchirurgical fMRI et DTI


Inconvénients

- « **brain shift** »
- limites de l'imagerie fonctionnelle
 - fMRI = aires activées mais non essentielles
 - DTI = aucune information fonctionnelle


Cartographie corticale et axonale per-opératoire




CECI EST



The problem of task selection




The problem of task selection













Duffau & al. 2013,
Brain & Language



Terminaisons corticales ?




Klinger's dissections : terminaisons ?




Potentiels évoqués cortico-corticaux

Patient 1




- Bipolar stimulation
- Language
- Face motor





Matsumoto R. *Brain* 2004

PECC : lien bidirectionnel, non bijectif

Patient 1




- Bipolar stimulation
- Language
- Face motor



pair of stimulation

- with CCEP_{PL→AL}
- without CCEP_{PL→AL}


Participation in Control





- Arcuate fasciculus (deep part of the superior longitudinal fasciculus)
- Lateral portion of the superior longitudinal fasciculus (anterior part)
- Lateral portion of the superior longitudinal fasciculus (posterior part)
- Inferior occipito-frontal fasciculus
- Uncinate fasciculus

- Inferior longitudinal fasciculus
- Frontal aslant tract
- U-fibers

Protocole PEAC



Protocole PEAC



Interpréter les PEAC : un défi pour les neurosciences

- ◆ Modélisation des PEAC

- modélisation locale

Modélisation bi-domaine des stimulations axonales





Fig. 5 Activated areas at a stimulation intensity of 5 mA. a Orthogonal setting. b Parallel setting

Interpréter les PEAC : un défi pour les neurosciences

◆ Modélisation des PEAC

- modélisation locale
- repérage du point stimulé en per-op dans l'IRM
 - = développer des algo de correction du brainshift
 - modèle anatomique des connections à partir du DTI
- modélisation des sites corticaux
 - simulation du PE à partir d'un modèle des couches corticales

Conclusion

- ◆ Images qui guident le chirurgien :
 - images de la tumeur
 - images du cerveau
- ◆ L'interprétation de ces images fait appel à des modèles biophysiques
- ◆ Le but ultime de ces modèles :
 - tumeur virtuelle patient-spécifique
→ guider la décision
 - cerveau virtuel patient-spécifique
→ guider le geste et la réparation

